CD56

CD56

CD56 Molekülinformation

Molecule Name
Neural cell adhesion molecule 1
Molekülalias
CD56
Drug Development Progress
Anzahl der klinischen Arzneimittel6
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Target-Alias
Neural cell adhesion molecule 1,CD56,NCAM1,NCAM,Neural Cell Adhesion Molecule, NCAM,CD56 Antigen,N-CAM-1,MSK39,NCAM-1,Antigen Recognized By Monoclonal Antibody 5.1H11
Molekülhintergrund
CD56 is a single transmembrane glycoprotein also known as NCAM (neural cell adhesion molecule), Leu-19, or NKH1. It is a member of the Ig superfamily. The 140 kD isoform is expressed on NK and NKT cells. CD56 is also expressed in the brain (cerebellum and cortex) and at neuromuscular junctions. Certain large granular lymphocyte (LGL) leukemias, small-cell lung carcinomas, neuronal derived tumors, myelomas, and myeloid leukemias also express CD56. CD56 plays a role in homophilic and heterophilic adhesion via binding to itself or heparan sulfate.

CD56 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Lorvotuzumab mertansineBB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1Phase 2 ClinicalImmunogen Inc
Carcinoma, Merkel Cell; Leukemia; Multiple Myeloma; Neuroblastoma; Neurofibrosarcoma; Ovarian Neoplasms; Pulmonary Blastoma; Rhabdomyosarcoma; Sarcoma, Synovial; Small Cell Lung Carcinoma; Wilms Tumor
Details
EB-DART-NK01EB-DART-NK01Phase 2 ClinicalBeijing Biotech
Small Cell Lung Carcinoma
Details
CUBT-906CUBT-906Phase 2 ClinicalCurative Biotechnology Inc
Glioblastoma
Details
GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute)bi-4SCAR GD2/CD56Phase 2 ClinicalShenzhen Geno-Immune Medical Institute
Neoplasms
Details
IN-B015IN-B-015; IN-B00004Phase 1 ClinicalHK inno.N Corporation
Neoplasms
Details
DXC-006DXC-006; DAC-006Phase 1 ClinicalHangzhou Dac Biotech Company Ltd
Hematologic Neoplasms; Lung Neoplasms; Solid tumours
Details